Sesamin has shown promise as an agent for the potential prevention and treatment of colorectal cancer due to its ability to inhibit hypoxia-induced colorectal cancer angiogenesis through the NF-κB/HIF-1α/VEGFA signaling pathway, both in vitro and in vivo33. Here, VEGFA is linked to colorectal cancer.